Explaining the relationship between race/ethnicity and pharmacy purchased syringes among injection drug users in New York City

Ethnicity and Disease

Volumn 14, Issue 4, 2004, Pages 589-596

  Fuller, Crystal M ^a,b   Galea, Sandro ^b   Blaney, Shannon ^b   Ompad, Danielle C ^b   Deren, Sherry ^c   Des Jarlais, Don ^d   Vlahor, David ^b  

^a Howard Hughes Medical Institute   (United States)

^b NEW YORK ACADEMY OF MEDICINE   (United States)

^c NATIONAL DEVELOPMENT AND RESEARCH INSTITUTES   (United States)

^d BETH ISRAEL MEDICAL CENTER   (United States)

Author keywords

HIV; Injection drug use; Pharmacy; Racial disparities

Indexed keywords

ADULT; ARTICLE; CAUCASIAN; CONTROLLED STUDY; DRUG ABUSE; ETHNIC DIFFERENCE; FEMALE; HEALTH PROGRAM; HISPANIC; HUMAN; INFORMATION PROCESSING; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; NEGRO; PHARMACY; POLICE; PREDICTION; PRESCRIPTION; PREVALENCE; RACE DIFFERENCE; SEX DIFFERENCE; SOCIAL ASPECT; SOCIAL BEHAVIOR; SYRINGE; TIME; UNITED STATES;

ADULT; CROSS-SECTIONAL STUDIES; ETHNIC GROUPS; FEMALE; HEALTH BEHAVIOR; HEALTH SERVICES ACCESSIBILITY; HIV INFECTIONS; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; NEW YORK CITY; PHARMACEUTICAL SERVICES; PREJUDICE; SEXUAL BEHAVIOR; SUBSTANCE ABUSE, INTRAVENOUS; SYRINGES;

EID: 7444259125     PISSN: 1049510X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Centers for Disease Control and Prevention (CDC), US Department of Health and Human Services. Final FY 2004 GPRA Annual Performance Plan 2003. Washington, DC: USDHHS.
2. Jones CP. Invited commentary: "race," racism, and the practice of epidemiology. Am J Epidemiol. 2001;154:299-304.
3. Jones CP. Levels of racism: a theoretic framework and a gardener's tale. Am J Public Health. 2000;90:1212-1215.
4. Schulz A, Williams D, Israel B, et al. Unfair treatment, neighborhood effects, and mental health in the Detroit metropolitan area. J Health Soc Behav. 2000;41:314-332.
5. Kressin NR, Petersen LA. Racial differences in the use of invasive cardiovascular procedures: review of the literature and prescription for future research. Ann Intern Med. 2001; 135:352-366.
6. Mayberry RM, Mili F, Ofili E. Racial and ethnic differences in access to medical care. Med Care Res Rev. 2000;57(suppl 1):108-145.
7. Winkleby MA, Robinson TN, Sundquist J, Kraemer HC. Ethnic variation in cardiovascular disease risk factors among children and young adults: findings from the Third National Health and Nutrition Examination Survey, 1988-1994. JAMA. 1999;281:1006-1013.
8. Schulz AJ, Williams DR, Israel BA, Lempert LB. Racial and spatial relations as fundamental determinants of health in Detroit. Milbank Q. 2002;80:677-707, iv.
9. Gee GC. A multilevel analysis of the relationship between institutional and individual racial discrimination and health status. Am J Public Health. 2002;92:615-623.
10. Lantz PM, Lynch JW, House JS, et al. Socioeconomic disparities in health change in a longitudinal study of US adults: the role of health-risk behaviors. Soc Sci Med. 2001;53: 29-40.
11. Williams DR. Race, socioeconomic status, and health. The added effects of racism and discrimination. Ann N Y Acad Sci. 1999;896: 173-188.
12. Balsa AI, McGuire TG. Prejudice, clinical uncertainty, and stereotyping as sources of health disparities. J Health Econ. 2003;22:89-116.
13. Thomas DL, Vlahov D, Solomon L, et al. Correlates of hepatitis C virus infections among injection drug users. Medicine. 1995; 74:212-220.
14. Kottiri BJ, Friedman SR, Neaigus A, Curtis R, Des J. Risk networks and racial/ethnic differences in the prevalence of HIV infection among injection drug users. J Acquir Immune Defic Syndr. 2002;30:95-104.
15. Kral AH, Bluthenthal RN, Booth RE, Watters JK. HIV seroprevalence among street-recruited injection drug and crack cocaine users in 16 US municipalities. Am J Public Health. 1998; 88:108-113.
16. Strathdee SA, van Ameijden EJ, Mesquita F, Wodak A, Rana S, Vlahov D. Can HIV epidemics among injection drug users be prevented? AIDS. 1998;12(suppl A):S71-S79.
17. Bastos FI, Strathdee SA, Dertke M, de Haan M. Drug use and the spread of HIV/AIDS in South America and the Caribbean. Drugs Educ Prev Policy. 1999;6:29-49.
18. Somlai AM, Kelly JA, Benotsch E, et al. Characteristics and predictors of HIV risk behaviors among injection-drug-using men and women in St. Petersburg, Russia. AIDS Educ Prev. 2002;14:295-305.
19. Kelly JA, Amirkhanian YA. The newest epidemic: a review of HIV/AIDS in Central and Eastern Europe. Int J STD AIDS. 2003;14: 361-371.
20. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report. Atlanta, Ga: CDC; 2001;13[1].
21. Centers for Disease Control and Prevention. Update: Syringe Exchange Programs - United States, 1998. MMWR. 2001;50(19 ):384-388.
22. Lurie P, Jones TS, Foley J. A sterile syringe for every drug user injection: how many injections take place annually, and how might pharmacists contribute to syringe distribution? J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18(suppl 1):S45-S51.
23. Lazzarini Z, Schoenbaurn EE, O'Neill CH. In New York City, syringe laws and regulations deter physicians and pharmacists from prescribing and selling syringes to persons who may be injection drug users. J Acquir Immune Defic Syndr Hum Retrovirol. 1998; 18(suppl 1):S141-S143.
24. Gostin LO, Lazzarini Z, Alexander D, Brandt AM, Mayer KH, Silverman DC. HIV testing, counseling, and prophylaxis after sexual assault. JAMA. 1994;271:1436-1444.
25. Case P, Meehan T, Jones TS. Arrests and incarceration of injection drug users for syringe possession in Massachusetts: implications for HIV prevention. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18(suppl 1):S71-S75.
26. Brahmbhatt H, Bigg D, Strathdee SA. Characteristics and utilization patterns of needle-exchange attendees in Chicago: 1994-1998. J Urban Health. 2000;77:346-358.
27. Rockwell R, Des J, Friedman SR, Perlis TE, Paone D. Geographic proximity, policy, and utilization of syringe exchange programmes. AIDS Care. 1999;11:437-442.
28. Rich JD, Strong L, Towe CW, McKenzie M. Obstacles to needle exchange participation in Rhode Island. J Acquir Immune Defic Syndr. 1999;21:396-400.
29. Bluthenthal RN, Kral AH, Lorvick J, Watters JK. Impact of law enforcement on syringe exchange programs: a look at Oakland and San Francisco. Med Anthropol. 1997;18:61-83.
30. Valleroy LA, Weinstein B, Jones TS, Groseclose SL, Rolfs RT, Kassler WJ. Impact of increased legal access to needles and syringes on community pharmacies' needle and syringe sales - Connecticut, 1992-1993. J Acquir Immune Defic Syndr Hum Retrovirol. 1995;10: 73-81.
31. Cotten-Oldenburg NU, Carr P, DeBoer JM, Collison EK, Novotny G. Impact of pharmacy-based syringe access on injection practices among injecting drug users in Minnesota, 1998 to 1999. J Acquir Immune Defic Syndr. 2001;27:183-192.
32. Novotny GA, Cotton-Oldenburg NU, Bond B, Tracy B. The Minnesota Pharmacy Syringe Access Initiative: a successful statewide program to increase injection drug user access to sterile syringes. J Am Pharm Assoc (Wash). 2002;42:S21-S22.
33. Fuller CM, Ahern J, Vadnai L, et al. Impact of increased syringe access: preliminary findings on injection drug user syringe source, disposal, and pharmacy sales in Harlem, New York. J Am Pharm Assoc (Wash). 2002;42: S77-S82.
34. Des Jarlais, McKnight C, Friedmann P. Legal syringe purchases by injection drug users, Brooklyn and Queens, New York City, 2000-2001. J Am Pharm Assoc (Wash). 2002;42: S73-S76.
35. Deren S, Fuller CM, Poujet ER, et al. Impact of expanding syringe access in New York on sources of syringes for IDUs in Harlem and the Bronx. Int J Drug Policy. 2003;14:373-379.
36. Center for Urban Epidemiologic Studies, New York Academy of Medicine. New York State Expanded Syringe Access Demonstration Program Evaluation: Evaluation Report to the Governor and the New York State Legislation. New York, NY: New York Academy of Medicine; January 15, 2003.
37. Kral AH, Bluthenthal RN, Booth RE, Watters JK. HIV seroprevalence among street-recruited injection drug and crack cocaine users in 16 US municipalities. Am J Public Health. 1998; 88:108-113.
38. Watters JK, Estilo MJ, Kral AH, Lorvick JJ. HIV infection among female injection-drug users recruited in community settings. Sex Transm Dis. 1994;21:321-328.
39. Schoenbaum EE, Hartel D, Selwyn PA, et al. Risk factors for human immunodeficiency virus infection in intravenous drug users. N Engl J Med. 1989;321:874-879.
40. Krieger N. Racial and gender discrimination: risk factors for high blood pressure? Soc Sci Med. 1990;30:1273-1281.
41. Krieger N, Sidney S. Racial discrimination and blood pressure: the CARDIA Study of young Black and White adults. Am J Public Health. 1996;86:1370-1378.
42. Finkelstein R, Tiger R, Greenwald R, Mukherjee R. Pharmacy syringe sale practices during the first year of expanded syringe availability in New York City (2001-2002). J Am Pharm Assoc (Wash . 2002;42:S83-S87.
43. Krieger N. A glossary for social epidemiology. J Epidemiol Community Health. 2001;55:693-700.
44. Sampson RJ, Wilson WJ. Toward a theory of race, crime, and urban inequality. In: Hagan J, Petersen RD, eds. Crime and Inequality. Stanford, Calif. Stanford University Press; 1995:37-54.
45. Obadia Y, Feroni I, Perrin V, Vlahov D, Moatti JP. Syringe vending machines for injection drug users: an experiment in Marseille, France. Am J Public Health. 1999;89: 1852-1854.